Phase I study of neoadjuvant S-1 plus cisplatin with concurrent radiation for biliary tract cancer (Tokyo Study Group for Biliary Cancer: TOSBIC02).

Yuta AbeOsamu ItanoYusuke TakemuraTakuya MinagawaHidenori OjimaMasahiro ShinodaMinoru KitagoHideaki ObaraNaoyuki ShigematsuYuko Kitagawa

Published in: Annals of gastroenterological surgery (2023)

We determined the recommended dose of neoadjuvant chemoradiotherapy for resectable cholangiocarcinoma. However, we terminated the trial due to a high incidence of morbidity and unexpected mortality.

Keyphrases

locally advanced
rectal cancer
lymph node
risk factors
squamous cell carcinoma
clinical trial
randomized controlled trial
radiation therapy
type diabetes
study protocol
cardiovascular events
phase ii
radiation induced
childhood cancer
open label